Both seladelpar (Livdelzi) and elafibranor (Iqirvo) were approved by the FDA in 2024, so they're both relatively new options. It's a great question, and the short answer is: both are considered reasonably safe, and neither is clearly "safer" than the other overall — they just have slightly different side effect profiles.
Show Full Answer
Both seladelpar (Livdelzi) and elafibranor (Iqirvo) were approved by the FDA in 2024, so they're both relatively new options. It's a great question, and the short answer is: both are considered reasonably safe, and neither is clearly "safer" than the other overall — they just have slightly different side effect profiles.
Here's a quick comparison:
Seladelpar side effects:
- Headache
- Abdominal pain
- Nausea
- Bloating
- Dizziness
Elafibranor side effects:
- Nausea, diarrhea, constipation
- Stomach pain
- Heartburn
- Weight changes
- Joint pain
- Fever or chills One reason some people may gravitate toward elafibranor is that it targets *two* proteins (PPAR-alpha and PPAR-delta), while seladelpar targets one (PPAR-delta). Some doctors may feel the dual-action approach offers broader benefits for managing bile acid buildup and liver inflammation.
That said, seladelpar has shown really promising results specifically for itching, with studies showing around 50% greater improvement compared to placebo — which is a big deal since itching is one of the most disruptive PBC symptoms.
Ultimately, the choice often comes down to individual symptoms, how well someone tolerates UDCA, and their doctor's recommendation. It's worth having a direct conversation with a hepatologist about which might suit your specific situation best.
June 24
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
